← All trials
NCT00000577
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 1993
- Primary completion
- —
- Completion date
- Jul 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- Pennsylvania State UniversityLead sponsor
- University of California, San FranciscoStudy chair
- University of California, San DiegoStudy chair
- University of WisconsinStudy chair
- University of PittsburghStudy chair
- Wake Forest UniversityStudy chair
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Harvard UniversityStudy chair
- Washington University in St. LouisStudy chair
- Pennsylvania State UniversityStudy chair
- University of Colorado, DenverStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.